Invention Grant
US09562227B2 Method for screening anticancer agent or SIP1/ZEB2 inhibitor using integrin alpha 5
有权
使用整合素α5筛选抗癌剂或SIP1 / ZEB2抑制剂的方法
- Patent Title: Method for screening anticancer agent or SIP1/ZEB2 inhibitor using integrin alpha 5
- Patent Title (中): 使用整合素α5筛选抗癌剂或SIP1 / ZEB2抑制剂的方法
-
Application No.: US13500502Application Date: 2008-12-05
-
Publication No.: US09562227B2Publication Date: 2017-02-07
- Inventor: Semi Kim , Hee Young Kang , Myoung Suk Choi , Mi-Ra Lee , Jin-San Yoo , Young Kyu Park
- Applicant: Semi Kim , Hee Young Kang , Myoung Suk Choi , Mi-Ra Lee , Jin-San Yoo , Young Kyu Park
- Applicant Address: KR Daejeon
- Assignee: Korea Research Institute of Bioscience & Biotechnology
- Current Assignee: Korea Research Institute of Bioscience & Biotechnology
- Current Assignee Address: KR Daejeon
- Agency: Lathrop & Gage LLP
- Agent Brian C. Trinque; Andrew T. Wilkins
- Priority: KR10-2008-0119773 20081128
- International Application: PCT/KR2008/007209 WO 20081205
- International Announcement: WO2010/061997 WO 20100603
- Main IPC: C12N15/113
- IPC: C12N15/113 ; G01N33/50
Abstract:
The present invention relates to a method for screening anticancer agent or SIP1/ZEB2 inhibitor using integrin alpha 5 (ITGA5), more precisely a method for measuring integrin alpha 5 expression pattern in SIP1/ZEB2 over-expressing cell line or SIP1/ZEB2 expression induced cell line, both treated with sample compounds, by comparing with that of the control. The method of the present invention facilitates screening of anticancer agent or SIP1/ZEB2 inhibitor simply by measuring integrin alpha 5 expression, so that it can be effectively applied in the field of medicine.
Public/Granted literature
- US20120201838A1 METHOD FOR SCREENING ANTICANCER AGENT OR SIP1/ZEB2 INHIBITOR USING INTEGRIN ALPHA 5 Public/Granted day:2012-08-09
Information query
IPC分类:
